Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy
To be successful, academic and commercial efforts to reintroduce phage therapy must ensure that only safe and efficacious products are used to treat patients. This raises a number of manufacturing, formulation, and delivery challenges. Since phages are biologics, robust manufacturing processes will...
Main Authors: | Michele Mutti, Lorenzo Corsini |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmicb.2019.02289/full |
Similar Items
-
Editorial: Standards in personalized phage therapy: from phage collection to phage production
by: Saija Kiljunen, et al.
Published: (2024-03-01) -
Phage Therapy
by: Joana Azeredo, et al.
Published: (2021-12-01) -
Phage–Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency
by: Chengxi Liu, et al.
Published: (2022-04-01) -
On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy
by: Sari eMattila, et al.
Published: (2015-11-01) -
ONCE MORE ABOUT PHAGE THERAPY: WHAT IS RIGHT, AND WHAT IS NOT
by: V. M. Popova, et al.
Published: (2016-12-01)